Abcuro
Ricky Motschwiller is Abcuro’s Controller. Ricky has over 10 years of experience in finance and accounting. Prior to Abcuro, he spend one and a half years at Constellation Pharmaceuticals as a Senior Accounting Manager & Assistant Controller, focused on monthly, quarterly, and annual financial closes for a publicly held company. Ricky spent five years at Solas Consulting, focusing on accounting and financial reporting for pre-public and recently public pharmaceutical and technology companies, and another five years at PricewaterhouseCoopers in Core Assurance.
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.